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Monocyte-lymphocyte cross-
communication via soluble CD163 
directly links innate immune 
system activation and adaptive 
immune system suppression 
following ischemic stroke
Grant C. O’Connell  1,2, Connie S. Tennant1, Noelle Lucke-Wold1, Yasser Kabbani3, Abdul R. 
Tarabishy3, Paul D. Chantler4,5 & Taura L. Barr1,6,7
CD163 is a scavenger receptor expressed on innate immune cell populations which can be shed from 
the plasma membrane via the metalloprotease ADAM17 to generate a soluble peptide with lympho-
inhibitory properties. The purpose of this study was to investigate CD163 as a possible effector of 
stroke-induced adaptive immune system suppression. Liquid biopsies were collected from ischemic 
stroke patients (n = 39), neurologically asymptomatic controls (n = 20), and stroke mimics (n = 20) 
within 24 hours of symptom onset. Peripheral blood ADAM17 activity and soluble CD163 levels were 
elevated in stroke patients relative to non-stroke control groups, and negatively associated with 
post-stroke lymphocyte counts. Subsequent in vitro experiments suggested that this stroke-induced 
elevation in circulating soluble CD163 likely originates from activated monocytic cells, as serum 
from stroke patients stimulated ADAM17-dependant CD163 shedding from healthy donor-derived 
monocytes. Additional in vitro experiments demonstrated that stroke-induced elevations in circulating 
soluble CD163 can elicit direct suppressive effects on the adaptive immune system, as serum from 
stroke patients inhibited the proliferation of healthy donor-derived lymphocytes, an effect which was 
attenuated following serum CD163 depletion. Collectively, these observations provide novel evidence 
that the innate immune system employs protective mechanisms aimed at mitigating the risk of post-
stroke autoimmune complications driven by adaptive immune system overactivation, and that CD163 is 
key mediator of this phenomenon.
Stroke triggers a systemic inflammatory response which results in a dramatic shift in the phenotype of the periph-
eral immune system. The innate arm of the peripheral immune system undergoes rapid activation, a phenome-
non which results in significant elevations in circulating neutrophil and monocyte counts in the hours following 
onset1,2. Conversely, the adaptive arm of the peripheral immune system shifts into a state of suppression, often 
characterized by a prolonged period of lymphopenia and limited antigen responsiveness2–4. While the patho-
physiological role of the innate immune response to stroke has been long appreciated, a growing body of evidence 
suggests that the adaptive immune response to stroke also critically influences patient outcome.
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It is likely that the state of adaptive immune suppression which develops in response to stroke serves to limit 
the possibility of an autoimmune response as the blood brain barrier becomes disrupted, and peripheral popula-
tions of lymphoid cells become exposed to unfamiliar central nervous system (CNS) peptides via the lesional and 
lymphatic accumulation of activated innate antigen presenting cells loaded with neural antigens5,6. Expectedly, 
heightened adaptive immune activity immediately following stoke has been shown to prolong the inflammatory 
state and promote secondary tissue damage, factors which can ultimately contribute to poor prognosis6,7. While 
the state of adaptive immune suppression is acutely protective, if prolonged, it can constitute a significant detri-
ment to recovery8–12. Patients which display prolonged adaptive immune suppression following stroke become 
highly susceptible to post-stroke infection13–16, which is one of the leading causes of death in the post-acute phase 
of care9. Despite the fact that it is becoming increasingly evident that this delicate balancing act between main-
tenance of self-tolerance and pathogen susceptibility plays a significant role in recovery, the mechanisms which 
drive the peripheral adaptive immune response to stroke are not yet fully understood.
CD163 is a membrane-bound scavenger receptor for extracellular hemoglobin which is believed to be 
expressed exclusively within the innate immune system17, where it is predominantly found on monocytes and 
macrophages18, and to a lesser extent on neutrophils19. Various stimuli can trigger CD163 ectodomain shed-
ding via cleavage by the metalloprotease ADAM metallopeptidase domain 17 (ADAM17)20,21, resulting in gen-
eration of a soluble truncated peptide (sCD163) which has been shown in multiple studies to directly interact 
with lymphocytes and inhibit antigen-induced proliferation22–24. Interestingly, genome-wide transcriptomic 
screening performed by our group recently identified CD163 as being robustly up-regulated in the peripheral 
blood of ischemic stroke patients within hours of symptom onset25. Furthermore, other groups have reported 
heightened ADAM17 activity in animal models of ischemic brain injury26–28, as well as stroke-induced increases 
in peripherally circulating levels of other ADAM17 substrates such as tumor necrosis factor alpha (TNFα) in 
human subjects29,30. Therefore, it is possible that stroke induces a rise in peripherally circulating levels of sCD163 
via coordinate increases in CD163 expression and ADAM17 activity; such a rise in sCD163 levels could subse-
quently contribute to suppression of the adaptive immune system via the inhibitory effects of sCD163 on lym-
phocyte activity. Thus, the primary objective of this study was to investigate sCD163 as a potential modulator of 
post-stroke adaptive immune suppression.
Results
Clinical and demographic characteristics. A cohort of 39 ischemic stroke patients was recruited along 
with two control groups, the first consisting of 20 neurologically asymptomatic subjects, and the second consisting 
of 20 acute stroke mimics. Ischemic stroke patients were significantly older than both neurologically asymptomatic 
controls and stroke mimics. Relative to neurologically asymptomatic controls, ischemic stroke patients displayed a 
more prevalent history of myocardial infarction and atrial fibrillation, and a higher percentage reported as taking 
anticoagulatory medications. Conversely, ischemic stroke patients were relatively well matched with stroke mimics 
in terms of all recorded cardiovascular disease risk factors, comorbidities, and medication status (Table 1).
ADAM17 activity and sCD163 levels are elevated in the peripheral blood following stroke. In 
order to determine whether stroke drives an increase in peripheral sCD163 production in vivo, peripheral 
venous blood was collected within 24 hours of symptom onset, and expression of ADAM17 and CD163 was 
assessed at both the RNA and protein level using a combination of qRT-PCR, enzyme activity assay, and ELISA. 
Transcriptional levels of both ADAM17 and sCD163 were significantly elevated in the whole blood of ischemic 
stroke patients relative to that of both control groups independently of age (Fig. 1A,B). Protein assays supported 
these observations, as ischemic stroke patients displayed significantly heightened cellular ADAM17 activity in 
peripheral blood total hemocyte fractions (Fig. 1C), as well as significantly elevated plasma levels of sCD163 
(Fig. 1D), once again in an age-independent fashion.
Expectedly, ADAM17 mRNA expression, CD163 mRNA expression, cellular TACE activity, and sCD163 lev-
els were significantly positively correlated across the collective patient population, allowing us to summarize the 
peripheral activity of the sCD163 production pathway in terms of a single composite variable using principal 
components analysis (Fig. 1E); this composite variable was positively associated with injury severity in terms of 
both the National Institutes of Health stroke scale (NIHSS) and infarct volume (Fig. 1F,G). While our relatively 
small sample size and the variability inherent to such measures of injury status kept these associations from reach-
ing statistical significance, these relationships tentatively inferred that the sCD163 production pathway is directly 
responsive to stroke pathology.
Taken as a whole, these collective observations provided associative evidence supporting our hypothesis that 
stroke induces a peripheral rise in sCD163 levels via increased ADAM17 activity.
sCD163 levels are negatively associated with post-stroke lymphocyte counts. To explore 
whether the elevations in sCD163 levels which we observed in ischemic stroke play a role in modulation of the 
stroke-induced peripheral immune response in vivo, we assessed the relationship between circulating sCD163 
levels and post-stroke leukocyte counts within the ischemic stroke group. Plasma sCD163 levels were significantly 
negatively associated with post-stroke absolute lymphocyte counts (Fig. 2A), as well as significantly positively 
associated with both absolute monocyte counts and absolute neutrophil counts (Fig. 2B,C). Collectively, these 
results provided in vivo associative evidence which supported our hypothesis that stroke-induced increases in 
myeloid-derived circulating sCD163 may contribute to post-stroke suppression of the adaptive immune system.
Stroke-induced circulating factors trigger monocytic sCD163 production in vitro. Next, we 
wanted to determine the direct effects of the post-stroke peripheral inflammatory milleu on ADAM17-mediated 
sCD163 shedding by peripheral innate immune cell populations. To do this, primary neutrophil and monocyte 
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cultures generated from the peripheral blood of twelve healthy donors (Supplementary Table 1) were treated 
with pooled serum samples derived from a subset of ten ischemic stroke patients, ten neurologically asympto-
matic controls, and ten stroke mimics which were relatively well matched in terms of clinical and demographic 
characteristics (Table 2). Serum incubation was performed in both the presence and absence of Marimastat, 
a broad-spectrum metalloproteinase inhibitor which is highly active against ADAM17, and cellular ADAM17 
activity and sCD163 production were assessed following three hours of treatment.
Generally, neutrophil cultures appeared phenotypically identical across all conditions when visually inspected 
following treatment (Fig. 3A). ADAM17 activity did appear to be elevated in neutrophil cultures treated with 
serum obtained from ischemic stroke patients relative to those treated with serum obtained from both neurolog-
ically asymptomatic controls and stroke mimics, however this increase was not statistically significant (Fig. 3B). 
Overall, neutrophil cultures appeared to generate relatively little sCD163, although a limited number of cultures 
treated with ischemic stroke serum did appear to exhibit increased sCD163 production in response to treatment. 
This effect was not widespread however, and no statistically significant differences were observed in sCD163 pro-
duction between cultures treated with ischemic stroke serum and those treated with serum from control groups 
(Fig. 3C). A second independent experiment using pooled serum samples derived from a separate sub-set of 
subjects (Supplementary Table 2) yielded similar results (Supplementary Figure 1).
Counter to what was observed in terms of neutrophil cultures, there were striking visual differences between 
monocyte cultures treated with serum derived from ischemic stroke patients and those treated with serum 
derived from control groups. Cultures treated with control serum displayed a mix of adherent and semi-adherent 
cells, however several cultures incubated with ischemic stroke serum contained large patches of cells which 
appeared highly adherent with prominent cytoplasmic vacuoles classically characteristic of a shift towards an 
activated phenotype (Fig. 4A). This phenomenon was quantifiable via image-based analysis, as point counting 
revealed that cultures treated with ischemic stroke serum contained a significantly greater number of adherent 
cells (Fig. 4B), as well as a significantly greater number of cells containing clearly defined vacuolar structures 
(Fig. 4C), in comparison to cultures treated with serum from control groups. Furthermore, cellular ADAM17 
activity was significantly elevated in cultures treated with ischemic stroke serum relative to those treated with 
serum from control groups (Fig. 4D), and supernatants recovered from cultures treated with ischemic stroke 
serum contained significantly higher concentrations of monocyte-derived sCD163 (Fig. 4E). Expectedly, the 
increase in monocytic sCD163 production which we observed upon stimulation with ischemic stroke serum was 
largely ablated by treatment with Marimastat (Fig. 4E), inferring that it was generated via the canonical sCD163 
pathway involving ADAM17. Once again, similar results (Supplementary Figure 2) were observed in a second 
independent experiment using pooled serum samples derived from a separate sub-set of subjects (Supplementary 
Table 2).
Collectively, these observations demonstrate that soluble factors present in peripheral circulation follow-
ing ischemic stroke have the capacity to trigger ADAM17-dependant sCD163 shedding from peripheral blood 
monocytes, however likely not from neutrophils.
Stroke-induced elevations in circulating sCD163 suppress lymphocyte proliferation in 
vitro. Lastly, we wanted to determine the direct effect of post-stroke-elevations in circulating sCD163 
levels on the capacity of the peripheral blood to support lymphocyte proliferation. To do this, primary lym-
phocyte cultures derived from healthy donors (Supplementary Table 1) were stimulated to proliferate using 
Group: p-value:
Asymptomatic (A; n = 20) Stroke Mimic (SM; n = 20) Ischemic Stroke (IS; n = 39) Main Test A vs. IS SM vs. IS
aAge (mean ± SD) 58.6 ± 11.1 58.0 ± 17.0 73.1 ± 13.3 <0.001* <0.001* <0.001*
bFemale n (%) 15 (75.0) 9 (45.0) 25 (64.1) 0.153 — —
aNIHSS (mean ± SD) 0.0 ± 0.0 4.7 ± 4.9 8.6 ± 7.5 <0.001* <0.001* 0.041*
bFamily history of stroke n (%) 11 (55.0) 5 (25.0) 15 (38.5) 0.014* 0.549 0.778
bHypertension n (%) 15 (75.0) 17 (85.0) 32 (82.1) 0.756 — —
bDyslipidemia n (%) 8 (40.0) 13 (65.0) 16 (41.0) 0.199 — —
bDiabetes n (%) 2 (10.0) 7 (35.0) 8 (20.5) 0.188 — —
bPrevious stroke n (%) 1 (5.00) 5 (25.0) 7 (17.9) 0.221 — —
bAtrial fibrillation n (%) 0 (00.0) 3 (15.0) 13 (33.3) 0.004* 0.005* 0.432
bMyocardial infarction n (%) 0 (00.0) 6 (30.0) 11 (28.2) 0.014* 0.021* 1.000
bHypertension medication n (%) 14 (70.0) 16 (80.0) 27 (69.2) 0.723 — —
bDiabetes medication n (%) 2 (10.0) 6 (30.0) 8 (20.5) 0.309 — —
bCholesterol medication n (%) 6 (30.0) 12 (60.0) 14 (35.9) 0.123 — —
bAnticoagulant or antiplatelet n (%) 1 (5.00) 12 (60.0) 23 (59.0) <0.001* <0.001* 1.000
bCurrent smoker n (%) 1 (5.00) 2 (10.0) 13 (33.3) 0.023* 0.043* 0.127
Table 1. Clinical and demographic characteristics. aMeans compared via one-way ANOVA with subsequent 
planned group-wise comparisons using Bonferroni-corrected two-sample two-tailed t-test; bProportions 
compared via 2 × 3 Fisher’s exact test with subsequent planned group-wise comparisons using Bonferroni-
corrected 2 × 2 Fisher’s exact test; NIHSS, National Institutes of Health stroke scale; SD, standard deviation.
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Figure 1. ADAM17 and CD163 expression in the peripheral blood following ischemic stroke. (A–D) Total 
ADAM17 mRNA expression, total CD163 mRNA expression, total cellular ADAM17 activity, and plasma 
sCD163 concentrations in peripheral blood biopsied from ischemic stroke patients, acute stroke mimics, and 
neurologically asymptomatic controls. mRNA expression values are presented as linearly-transformed values 
scaled relative to the mean of the asymptomatic control group. Inter-group comparison of means was performed 
using one-way ANCOVA with age as a covariate; in the case of a significant test, subsequent planned group-wise 
comparisons of age-adjusted values were performed via Bonferroni-corrected two-sample two-tailed t-test. 
ANCOVA was performed using log-transformed data in order to meet homogeneity of variance assumptions. 
(E) Correlation matrix depicting the group-wide collective relationships between peripheral blood ADAM17 
mRNA expression, CD163 mRNA expression, ADAM17 activity, and sCD163 levels, along with the loadings 
of the single principal component used to summarize sCD163 pathway activity. Strength of correlations were 
tested using Pearson’s r and p-values were adjusted for multiple tests via the Bonferroni correction. (F–G) 
Relationships between sCD163 pathway activity and injury severity as determined by NIHSS and infarct volume 
within the ischemic stroke group. Strength of correlations were tested using Spearman’s rho.
Figure 2. Relationship between plasma sCD163 levels and post-stroke peripheral immune status. (A–C) 
Relationships between plasma sCD163 levels and absolute lymphocyte counts, absolute monocyte counts, 
and absolute neutrophil counts in the peripheral blood of ischemic stroke patients. Strength of correlational 
relationships were tested via Spearman’s rho.
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phytohemagglutinin-M (PHA-M) for 72 hours in the presence of pooled serum samples generated from ischemic 
stroke patients, neurologically asymptomatic controls, and stroke mimics (Table 2); pooled serum samples were 
either unmanipulated in terms of sCD163 levels or partially depleted of sCD163 using immunoprecipitation 
prior to treatment (Fig. 5A). Bromodexyuridine (BrdU) incorporation was monitored over the final 24 hours of 
stimulation and used to assess proliferation rates.
Consistent with prior reports31, visual observations suggested decreased proliferative activity in lymphocyte 
cultures treated with unmanipulated ischemic stroke serum relative to those treated with unmanipulated serum 
from control groups, as they appeared to contain smaller and more diffuse clusters of blasting lymphocytes. 
However, visual indications suggested that the inhibitory effect of ischemic stroke serum was at least moder-
ately counteracted by depletion of sCD163 (Fig. 5B). In agreement with these visual observations, we observed 
significantly lower levels of BrdU incorporation in lymphocytes stimulated in the presence of unmanipulated 
ischemic stroke serum relative to those which were stimulated in the presence of unmanipulated serum derived 
from control groups, an effect which was partially ablated as a result of sCD163 depletion (Fig. 5C). A second 
independent experiment using pooled serum samples derived from a separate subset of subjects (Supplementary 
Table 2) yielded similar results (Supplementary Figure 3). Taken together, these results novelly suggest that 
post-stroke elevations in circulating levels of sCD163 can have direct inhibitory effects on the proliferative capac-
ity of lymphocytes.
Discussion
The primary objective of this work was to determine the role of CD163 within the context of stroke immuno-
pathology. We hypothesized that coordinate elevations in CD163 expression and ADAM17 activity induced by 
stroke could drive increases in circulating levels of sCD163, which could ultimately contribute to suppression of 
the peripheral adaptive immune system via the known inhibitory effects of sCD163 on lymphocyte activity. Our 
collective findings supported this hypothesis, and suggest that sCD163 plays a novel role as a factor which syner-
gistically links stroke-induced activation of the innate immune system and suppression of the adaptive immune 
system. Such a mechanism provides a unique example which suggests that the innate immune system employs 
protective measures aimed at mitigating the risk of post-stroke autoimmune complications driven by adaptive 
immune system overactivation.
Observations of elevated levels of sCD163 in the peripheral blood of ischemic stroke patients, along with the 
fact that these elevations were negatively associated with lymphocyte counts, provided in vivo associative evi-
dence supporting our hypothesis that CD163 plays a role in modulation of the adaptive immune system following 
stroke. Furthermore, our in vitro observations suggested that this stroke-driven increase in circulating sCD163 
most likely originates from activated peripheral blood monocytes, as serum from ischemic stroke patients stim-
ulated ADAM17-dependant sCD163 production in monocyte cultures generated from the peripheral blood of 
healthy individuals. Our in vitro observations further suggested that stroke-induced elevations in circulating 
sCD163 have the capacity to elicit direct suppressive effects on the adaptive immune system, as depletion of 
sCD163 from ischemic stroke patient-derived serum was able to partially rescue its capacity to support lympho-
cyte proliferation. Collectively, our findings infer a mechanism in which peripherally circulating factors induced 
by stroke trigger ADAM17-dependant CD163 shedding by monocytes, driving an increase in sCD163 levels 
which act to suppress peripheral lymphocyte activity; this mechanism likely serves as a means of maintaining 
Group: p-value:
Asymptomatic (A; n = 10) Stroke Mimic (SM; n = 10) Ischemic Stroke (IS; n = 10) Main Test A vs. IS SM vs. IS
aAge (mean ± SD) 57.5 ± 11.1 56.4 ± 17.1 63.5 ± 14.3 0.536 — —
bFemale n (%) 8 (80.0) 5 (50.0) 5 (50.0) 0.348 — —
aNIHSS (mean ± SD) 0.0 ± 0.0 1.6 ± 2.4 6.6 ± 6.9 0.007* <0.001* <0.001*
bFamily history of stroke n (%) 5 (50.0) 2 (20.0) 4 (40.0) 0.510 — —
bHypertension n (%) 9 (90.0) 8 (80.0) 8 (80.0) 1.000 — —
bDyslipidemia n (%) 5 (50.0) 7 (70.0) 4 (40.0) 0.534 — —
bDiabetes n (%) 1 (10.0) 1 (10.0) 1 (10.0) 1.000 — —
bPrevious stroke n (%) 1 (10.0) 1 (10.0) 2 (20.0) 1.000 — —
bAtrial fibrillation n (%) 0 (00.0) 2 (20.0) 3 (30.0) 0.321 — —
bMyocardial infarction n (%) 0 (00.0) 1 (10.0) 2 (20.0) 0.754 — —
bHypertension medication n (%) 9 (90.0) 8 (80.0) 7 (70.0) 0.847 — —
bDiabetes medication n (%) 1 (10.0) 1 (10.0) 1 (10.0) 1.000 — —
bCholesterol medication n (%) 2 (20.0) 7 (70.0) 3 (30.0) 0.110 — —
bAnticoagulant or antiplatelet n (%) 1 (10.0) 5 (50.0) 6 (60.0) 0.065 — —
bCurrent smoker n (%) 1 (10.0) 1 (10.0) 2 (20.0) 1.000 — —
Table 2. Clinical and demographic characteristics of subject sub-populations used for in vitro experiments. 
aMeans compared via one-way ANOVA with subsequent planned group-wise comparisons using Bonferroni-
corrected two-sample two-tailed t-test; bProportions compared via 2 × 3 Fisher’s exact test with subsequent 
planned group-wise comparisons using Bonferroni-corrected 2 × 2 Fisher’s exact test; NIHSS, National 
Institutes of Health stroke scale; SD, standard deviation.
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self-tolerance as the blood brain barrier becomes disrupted and peripheral lymphoid populations become 
exposed to activated innate antigen presenting cells loaded with unfamiliar neural antigens (Fig. 6).
To our knowledge, our results are the first to demonstrate a direct role for the innate immune system in per-
petuating stroke-induced suppression of the peripheral adaptive immune system. While our results highlighted 
sCD163 as a means of such cross-communication, it is likely other innate-derived factors function to mediate 
the adaptive immune response to stroke via similar mechanisms. This notion is accentuated by the fact that 
ablation of sCD163 from stroke-derived serum was not adequate to fully rescue its capacity to support lym-
phocyte proliferation, inferring that there are a multitude of other soluble factors present in post-stroke periph-
eral circulation which have similar inhibitory effects. While the origins of these factors are inevitably diverse, 
it is likely that some arise via a similar mechanism as sCD163, as biological mechanisms are often redundant32. 
Interesting from this regard is cluster of differentiation 14 (CD14), a membrane-bound pattern recognition 
receptor which is largely exclusive to the innate immune system33,34. Much like CD163, CD14 can be shed via a 
metalloproteinase-dependent mechanism to generate a soluble protein (sCD14) which has been shown to directly 
interact with lymphocytes and exert suppressive effects35,36. Preliminary results from our laboratory suggest that 
circulating levels of sCD14 are also elevated in response to stroke, and further exploration may reveal that sCD14 
plays a similar role as sCD163 in modulation of the peripheral adaptive immune response.
While this study identified a clear role for sCD163 in stroke immunopathology in terms of its end-action, our 
experiments did not look to identify the soluble factors present in peripheral circulation following stroke which 
are responsible for triggering the shedding of CD163 from monocytes. It is plausible that this phenomenon is 
likely driven by a synergistic combination of stroke-induced damage associated molecules (DAMs), cytokines, 
and hormones, as members of the aforementioned families of factors are known to stimulate CD163 shedding. 
Notable from this standpoint is extracellular hemoglobin, a DAM which has been previously demonstrated as 
being acutely elevated in peripheral circulation following stroke as a result of intravascular and extravascular 
hemolysis37. Free hemoglobin has been characterized as a potent inducer of CD163 shedding38, and thus, may 
help drive production of sCD163 in response to stroke. Along similar lines, levels of interleukin-6, cortisol, and 
reactive oxygen species are all known to be elevated acutely in stroke pathology29,39,40, and all have been shown 
to promote sCD163 production41,42. Further exploration into these and other potential molecular signals which 
may trigger sCD163 generation within the context of stroke could not only provide a more complete picture of the 
mechanisms identified in this study, but a better understanding of post-stroke adaptive immune suppression as a 
whole, as the factors which drive post-stroke sCD163 production likely exert suppressive effects on the peripheral 
immune system via multiple parallel mechanisms.
While our findings are exciting, it is important to note that potentially confounding the interpretation of 
our results is the fact that elevations in sCD163 have been previously reported in atherosclerosis as a result of 
excessive intravascular macrophage activity within atherosclerotic plaques43. As atherosclerosis is closely linked 
with stroke as one of its primary pathogenic drivers44, it leaves open the possibility that our results were ather-
osclerosis driven, and not by the acute event of stroke itself. However, we find this scenario unlikely, as subjects 
Figure 3. Effects of ischemic stroke serum on neutrophil ADAM17-dependant sCD163 production. (A) 
Morphology of healthy donor-derived neutrophils following three hours incubation with 10% serum obtained 
from ischemic stroke patients and control subjects, in either the presence or absence of the ADAM17 inhibitor 
Marimastat. (B) ADAM17 activity in neutrophil lysates collected following treatment. (C) Neutrophil-derived 
sCD163 levels in cell culture supernatants collected following treatment, presented as the difference in sCD163 
levels observed between cell culture supernatants and serum-supplemented media incubated in the absence 
of cells. Means were compared via repeated measures one-way ANOVA; the Greenhouse-Geisser correction 
was applied to account for non-sphericity. In the case of a significant test, subsequent planned group-wise 
comparisons were performed using Bonferroni-corrected paired two-tailed t-test; planned comparisons are 
indicated by brackets.
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in our control groups were relatively well matched with ischemic stroke patients in terms of the prevalence of 
cardiovascular disease risk factors associated with atherosclerosis. We suspect that sCD163 levels are chronically 
heightened with underlying cardiovascular pathology and become further elevated in response to the acute event 
of stroke itself. Supporting our notion that the elevations in sCD163 which we observed in ischemic stroke were 
a direct result of the stroke-induced neurological insult is the fact that it has recently been reported that levels of 
macrophage-derived sCD163 are elevated in the cerebrospinal fluid of pediatric traumatic brain injury patients45, 
providing concurrent evidence that cerebral injury has the capacity to directly trigger increased sCD163 produc-
tion independent of atherosclerotic pathology.
We feel it is also important to note that our exclusive use of primary human cell cultures and specimens 
throughout our experiments posed a unique set of challenges, and was inherently associated with experimental 
limitations. For example, our use of immunoprecipitation to deplete serum of CD163 in our lymphocyte pro-
liferation experiments leaves open the possibility that the difference in proliferation rates which we observed 
between lymphocytes treated with CD163-depleted and CD163-normal ischemic stroke serum was driven by the 
removal of an off-target molecule other than CD163 via a non-specific antibody interaction. We find this scenario 
unlikely however, as we used a well characterized capture antibody which has been demonstrated in numerous 
prior investigations to have a high degree of specificity for CD16338,46–49, and performed immunoprecipitation at 
low temperatures using minimal concentrations of antibody to mitigate the risk of non-specific binding events.
Another potential experimental confound lies in our use of Marimastat to inhibit ADAM17 in vitro; because 
Marimastat has activity against multiple proteases (MMP1, MMP2, MMP3, MMP7, MMP9, and MMP14 in 
addition to ADAM17)50, it is possible that the ablation of stroke serum-induced monocytic sCD163 production 
we observed upon treatment with Marimastat was the result of the inhibition of a shedase other than ADAM17. 
However, we find this unlikely when considering that ADAM17 is the only known target of Marimastat which 
is believed to be involved in cleavage of CD16320, and even further unlikely when considering that we observed 
a strong correlation between ADAM17 activity and sCD163 levels in the peripheral blood of stroke patients in 
vivo. With regards to both aforementioned cases of potential experimental confounds, it could be argued that the 
experimental questions at hand could have been more efficiently and definitively addressed through the genetic 
manipulation of CD163 and ADAM17 in a murine model of stroke; however, it is becoming increasingly evident 
‡
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Figure 4. Effects of ischemic stroke serum on ADAM17-dependant sCD163 production by monocytes. (A) 
Morphology of healthy donor-derived monocytes following three hours incubation with 20% serum obtained 
from ischemic stroke patients and control subjects, in either the presence or absence of the ADAM17 inhibitor 
Marimastat. White arrowheads indicate cytoplasmic vacuoles. (B–C) Proportions of adherent monocytes and 
monocytes containing clearly defined vacuolar structures upon post-treatment imaging and quantification. (D) 
ADAM17 activity in monocyte lysates collected following treatment. (E) Monocyte-derived sCD163 levels in 
cell culture supernatants collected following treatment, presented as the difference in sCD163 levels observed 
between cell culture supernatants and serum-supplemented media incubated in the absence of cells. Means 
were compared via repeated measures one-way ANOVA; the Greenhouse-Geisser correction was applied to 
account for non-sphericity. In the case of a significant test, subsequent planned group-wise comparisons were 
performed using Bonferroni-corrected paired two-tailed t-test; planned comparisons are indicated by brackets.
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that experimental stroke models poorly recapitulate several aspects of pathology51,52, and that in general, immu-
nological responses in laboratory rodents are often poorly analogous to those in humans53,54. For these reasons, 
we feel the human-central experimental design used in this study provides tremendous translational value, in 
spite of the aforementioned potential limitations.
From a broader perspective, our findings are intriguing as they demonstrate a departure from the often com-
partmentalized view of stroke immunopathology. While there are exceptions, research regarding stroke immu-
nopathology has long treated the adaptive and innate immune responses as independent entities, however our 
results and recent results of others suggest that these responses are synergistically linked via direct mechanisms. 
This realization is of utmost importance with regards to the current push towards the development of novel stroke 
therapeutics which target the peripheral immune system. Currently, experimental immune therapies are being 
developed which largely aim to improve stroke outcome via one of two often discrete avenues: either by inhib-
iting the acute innate immune response to stroke as means of limiting excessive tissue damage and mitigating 
the risk of negative secondary cerebrovascular events such as edema and hemorrhagic transformation55–57, or by 
post-acutely stimulating the peripheral adaptive immune system as a means of limiting the risk of complications 
induced by post-stroke infection58–61. However, immunotherapeutics proposed along this line of thinking often 
Figure 5. Influence of post-stroke peripheral blood sCD163 levels on the capacity to support lymphocyte 
proliferation. (A) Pre and post-immunoprecipitation concentrations of sCD163 in pooled serum samples 
obtained from ischemic stroke patients and controls, immunoprecipitated using either anti-CD163 polyclonal 
antibody or isotype control. (B) Morphology of healthy donor-derived lymphocytes following 72 hours of PHA-
stimulated proliferation in the presence of 20% post-immunoprecipitation pooled serum. White arrowheads 
indicate clusters of blasting lymphocytes. (C) BrdU incorporation over the final 24 hours of treatment. Means 
were compared via repeated measures one-way ANOVA; the Greenhouse-Geisser correction was applied to 
account for non-sphericity. In the case of a significant test, subsequent planned group-wise comparisons were 
performed using Bonferroni-corrected paired two-tailed t-test; planned comparisons are indicated by brackets.
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fail to account the possible interplay between the adaptive and innate immune systems, and the potential reper-
cussions that could stem from modulating one response without consideration for the other.
A perfect example in this regard is the fact that ADAM17 inhibitors are often cited as a potential stroke thera-
peutic under the premise that they could ultimately limit excessive innate-driven inflammation and its associated 
complications via a reduction in TNFα production62–65. However, our results clearly demonstrate that inhibition 
of ADAM17 within the innate immune system could directly interfere with mechanisms which act to suppress 
the adaptive immune system, an unintended effect which could put patients at elevated risk for the development 
of long-term autoimmune complications associated with loss of CNS self-tolerance. Such an example highlights 
the necessity for a global view regarding the peripheral immune system in terms of the development of novel 
stroke immunotherapeutics. Unfortunately, therapeutic design from such a perspective is currently unrealistic, 
as the mechanisms which drive the stroke-induced peripheral immune response, particularly that of the adaptive 
immune system, are still largely unknown. This current gap in knowledge may underlie the reality that stroke 
immunotherapeutics have thus-far been largely unsuccessful66. Further future work which aims to character-
ize the peripheral immune response to stroke and its underlying mechanisms from a panoptic systems biology 
approach, preferably within human-centric models, would likely generate the foundational basis for the develop-
ment of stroke immunotherapeutics with higher chances for clinical success.
Collectively, our results demonstrate a novel role for CD163 as factor which mechanistically couples stroke 
induced-activation of the peripheral innate immune system and suppression of the peripheral adaptive immune 
system. Our results provide a unique example which suggests that the innate immune system employs protective 
mechanisms aimed at mitigating the risk of post-stroke autoimmune complications driven by adaptive immune 
system overactivation. Further work which looks to characterize similar pathways of cross-communication 
between the innate and adaptive immune systems within the context of stroke would likely provide a better 
understanding of stroke pathology as a whole, and allow for more informed development of stroke-targeted 
immunotherapeutics.
Methods
Patients. Acute ischemic stroke patients, acute stroke mimics, and neurologically asymptomatic controls 
were recruited at Ruby Memorial Hospital, Morgantown, WV. Ischemic stroke patients displayed definitive radi-
ographic evidence of vascular ischemic pathology on magnetic resonance imaging (MRI) or computed tomogra-
phy (CT) according to the established criteria for diagnosis of acute ischemic cerebrovascular syndrome (AICS)67, 
and diagnoses were confirmed by an experienced neurologist. Patients admitted to the emergency department 
as suspected strokes based on the overt presentation of stroke-like symptoms, but receiving a definitive nega-
tive diagnosis for stroke upon neuroradiological imaging and clinical evaluation were identified as acute stroke 
mimics67. Discharge diagnoses of stroke mimics included cases of seizures, complex migraines, hypertensive 
encephalopathy, and other non-stroke conditions which induce neurological symptoms. Prospective subjects 
Figure 6. Proposed role for CD163 in modulation of the stroke-induced peripheral immune response. Stroke-
driven elevations in circulating levels of damage associated molecules (DAMs), proinflammatory cytokines, and 
hormones coordinately trigger innate immune system activation and ADAM17-dependant CD163 shedding by 
monocytes, resulting in increased generation of sCD163. Heightened circulating sCD163 levels subsequently act 
to suppress lymphocyte activity, likely as a means of limiting the risk of a CNS-directed autoimmune response 
resulting from adaptive immune system activation.
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were excluded if they received a non-definitive diagnosis, displayed evidence of hemorrhagic pathology, pre-
sented with cancer as a co-pathology, reported a prior hospitalization within 90 days, or were under 18 years of 
age. Blood was sampled within 24 hours of onset, as determined by the time the patient was last known to be free 
of stroke-like symptoms. In the case of patients who received thrombolytic therapy, blood samples were collected 
prior to the administration of recombinant tissue plasminogen activator (rtPA). Injury severity was determined 
according to the NIHSS at the time of blood draw. Control subjects were deemed neurologically normal by a 
trained neurologist at the time of enrolment. Demographic information was collected from either the subject 
or significant other by a trained clinician. Procedures were approved by the institutional review boards of West 
Virginia University and Ruby Memorial Hospital (IRB protocol 1410450461R001), and all experiments were 
performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from 
all subjects or their authorized representatives prior to study procedures.
Neuroradiological imaging. Neuroradiological imaging was performed using either MRI or CT within 
24 hours of symptom onset. CT imaging was performed on either a Toshiba Aquilion 64 or Toshiba Aquilion 320 
scanner (5 mm slices acquired at 120 KVp, 250 mA). MRI imaging was performed using either a Siemens Aera or 
Siemens Verio scanner (5 mm slices, 5 mm inter-slice gap, acquired via diffusion-weighted echoplanar imaging 
with a B-factor of 1000 s/mm2). The BrainLAB iPlan Neuroradiology software package (BrainLAB, Westchester, Ill) 
was used to calculate infarct volume via manual tracing, and all infarct volume calculations were verified by an 
experienced neurologist.
Blood collection. Parallel peripheral venous whole blood samples were collected from subjects via PAXgene 
RNA tubes (Qiagen, Valencia, CA), K2 EDTA Vacutainers (Becton Dickenson, Franklin Lakes, NJ), and serum 
separator tubes (Becton Dickenson). PAXgene RNA tubes were frozen immediately and stored at −80 °C until 
RNA extraction. K2 EDTA tubes were stored at room temperature until white blood cell differential (less than 
30 minutes), plasma isolation (less than 30 minutes), or leukocyte isolation (performed immediately). Serum sep-
arator tubes were stored at room temperature until serum isolation (less than 30 minutes).
Isolation of serum and plasma. For plasma isolation, EDTA-treated blood was spun at 2,000 * g for 
10 minutes to sediment hemocytes. Plasma was collected for ELISA, and the total hemocyte fraction was retained 
for subsequent protein extraction and ADAM17 activity assay. Plasma was additionally spun at 10,000 * g for 
10 minutes to remove any residual blood cells or debris. For serum isolation, serum separator tubes were incu-
bated at room temperature for a minimum of 15 minutes to allow for coagulation, and subsequently spun at 
2,000 * g for 10 minutes to sediment the resulting thrombus. Resultant samples were stored at −80 °C until 
analysis.
RNA extraction and quantitative reverse transcription PCR. Whole blood RNA was extracted from 
PAXgene tubes via the PreAnalytiX PAXgene blood RNA kit (Qiagen) and automated using the QIAcube sys-
tem (Qiagen). Quantity and purity of isolated RNA was determined via spectrophotometry (NanoDrop, Thermo 
Scientific, Waltham, MA). cDNA was generated from purified RNA using the Applied Biosystems high capacity 
reverse transcription kit. For qPCR, target sequences were amplified from 10 ng of cDNA input using sequence 
specific primers (Supplementary Table 3) and detected via SYBR green (PowerSYBR, Thermo-Fisher) on the 
RotorGeneQ thermocycling system (Qiagen). All reactions were performed in triplicate. Raw amplification plots 
were background corrected and CT values were generated via the RotorGeneQ software package. Transcripts of 
B2M, PPIB, and ACTB were amplified as references and normalization was performed using the NORMA-Gene 
data-driven normalization algorithm as described previously68,69. Statistical testing was performed using normal-
ized CT values, and data were linearly transformed and scaled relative to the mean of the control group for visual 
representation per the methodology described by Schittgen and Livak70.
White blood cell differential. Complete blood count was obtained from EDTA-treated blood via com-
bined optical flow cytometry and cellular impedance using an automated clinical hematology analyzer (Cell-Dyn, 
Abbott Diagnostics, Santa Clara, CA).
Isolation of primary leukocytes for cell culture. Starting with 30 mLs of healthy donor-derived 
EDTA-treated blood, peripheral blood mononuclear cells (PBMCs) were separated from polymorphonuclear 
cells (PMNs) and red blood cells (RBCs) via centrifugation over a polysaccharide-sodium diatrizoate density 
gradient (Lymphoprep, 1.077 g/mL, StemCell Technologies) for 30 minutes at 400 * g. Resultant interphase PBMC 
fractions were collected, resuspended in RPMI 1640 (Life Technologies, Grand Island, NY) containing 10% autol-
ogous serum, separated into two aliquots, and set aside at room temperature. Pelleted PMN/RBCs were immedi-
ately placed on ice for PMN enrichment via RBC lysis induced by two 5 minute incubations with a 1:10 volume of 
ice cold ammonium chloride (ACK) buffer. The resultant PMNs were rinsed in ice cold phosphate buffered saline 
(PBS), counted via automated cytometer (Cellmeter×1, Nexcelom Bioscience, Lawrence, MA), and immediately 
plated for experiments.
Following PNM isolation, monocytes were further enriched from one aliquot of PBMCs via a second round 
of density gradient centrifugation as described by Menck et al.71. Briefly, PBMC suspensions were layered over 
an iso-osmotic 46% Percoll (1.131 g/mL, Sigma Aldrich) solution prepared in RPMI 1640 containing 10% autol-
ogous serum and centrifuged at 500 * g for 30 minutes. Monocytes were collected from the resultant interphase, 
rinsed in PBS, counted, and immediately plated for experiments.
Following PMN and monocyte isolation, the remaining aliquot of PBMCs was rinsed in PBS and seeded in 
T75 flasks for lymphocyte expansion. Lymphocytes were expanded for 72 hours under standard mammalian cell 
www.nature.com/scientificreports/
1 1SCIENTIfIC RepORTs | 7: 12940  | DOI:10.1038/s41598-017-13291-6
culture conditions in a growth media comprised of RPMI 1640 containing 2% PHA-M (Gibco, Grand Island, 
NY), 2 mM L-Alanyl-Glutamine (GlutaMAX, Gibco), 25 mM HEPES (Gibco), 50 uM BME (Gibco), and 1% 
antibiotic-antimycotic (Gibco), supplemented with 10% autologous serum. Following expansion, actively prolif-
erating lymphocytes were rinsed in PBS, counted, and plated for experiments.
Neutrophil culture. Neutrophils from healthy donors were seeded in 12-well plates at a density of 7.5 * 105 
cells per well in 250 uL of GlutaMax-supplemented RPMI 1640 containing 10% patient serum along with 
either Marimastat (10 uM, Sigma Aldrich, St-Louis, MO) or vehicle (DMSO, Fisher Scientific). Following three 
hours of incubation under standard mammalian culture conditions, cells were lysed in NP40 lysis buffer (Life 
Technologies) and cellular ADAM17 activity was assessed via enzyme activity assay. Cell culture supernatants 
were collected and concentrations of sCD163 were quantified via ELISA; levels of neutrophil-derived sCD163 
were determined by subtracting the concentration of sCD163 in media incubated without cells from the concen-
trations of sCD163 observed in cell culture supernatants.
Monocyte culture. Monocytes from healthy donors were seeded in 12-well plates at a density of 1 * 106 
cells per well in 250 uL of GlutaMax-supplemented RPMI 1640 containing 20% patient serum along with either 
Marimastat (10 uM) or vehicle (DMSO). Following three hours of incubation under standard mammalian culture 
conditions, cells were lysed in NP40 lysis buffer and cellular ADAM17 activity was assessed via enzyme activity 
assay. Cell culture supernatants were collected and concentrations of sCD163 were quantified via ELISA; levels 
of monocytes-derived sCD163 were determined by subtracting the concentration of sCD163 in media incubated 
without cells from the concentrations of sCD163 observed in cell culture supernatants.
sCD163 depletion from human serum. sCD163 was depleted from pooled serum samples via immu-
noprecipitation using biotinylated goat polyclonal antibody raised against the extracellular region of CD163 
(AF1607, R&D Systems, Minneapolis, MN). Biotinylated normal goat IgG (AF108, R&D Systems) was used as 
an isotype immunoprecipitation control. Immunoglobulins were conjugated to polymer-coated superparamag-
netic beads (Dynabeads Streptavidin T1, Thermo Fisher, Waltham MA) at a ratio of 10 ug of immunoglobulins 
per 1 mg of beads. For immunoprecipitation, 5 mL of pooled serum was precleared with normal IgG conjugated 
beads, and then incubated with 0.5 mg of either normal IgG conjugated beads or anti-CD163 conjugated beads 
for 30 minutes at 4 °C. Beads were subsequently separated from serum samples via multiple rounds of magnetic 
separation. Immunoprecipitation was performed under aseptic conditions and serum was filtered at 14 microns 
following immunoprecipitation to remove potential microbial contaminants prior to cell culture. Depletion of 
sCD163 was subsequently confirmed via ELISA.
Lymphocyte proliferation assay. Expanded lymphocytes from healthy donors were seeded in 48 well 
plates at 5*104 cell per well in 200 uL growth media supplemented 20% pooled patient serum. Following 48 hours 
of culture, BrdU (Roche Life Sciences, Indianapolis, IN) was added to cultures at a final concentration of 20 uM. 
After allowing for 24 hours for BrdU incorporation, lymphocytes were adhered via centrifugation and fixed for 
BrdU quantification. Incorporated BrdU was quantified via colorimetric ELISA (Roche Life Sciences) per man-
ufacture instructions.
sCD163 ELISA. sCD163 was measured in plasma samples and cell culture supernatants using a commercially 
available colorimetric ELISA assay (RAB0082, Sigma-Aldrich). Plasma samples were diluted 1:50, neutrophil cell 
culture supernatants were diluted 1:5, and monocyte cell culture supernatants were diluted 1:10 prior to analysis. 
Absorbance readings were obtained using the Synergy HT multi-mode microplate reader (BioTek, Winooski 
VT). Due to the potential confound of hemolysis on concentrations of leukocyte derived analytes, plasma samples 
were screened for hemolysis prior to ELISA. Plasma absorbance was measured at 385 and 414 nm via spectropho-
tometry (NanoDrop, Thermo Scientific, Waltham, MA) and used to calculate a hemolysis score as described by 
Appierto et al.72. Plasma samples with detectable hemolysis were excluded from analysis.
ADAM17 activity assay. Total hemocyte fractions were thawed, mixed with NP-40 lysis buffer 
(Thermo Fisher) at a 1 to 1 ratio, and depleted of hemoglobin via the HemogloBind hemoglobin removal kit 
(Biotech Support Group, Monmouth Junction, NJ) as described by Park et al.73. Protein concentrations of 
hemoglobin-depleted total hemocyte lysates and cell culture lysates were determined via DC-protein assay 
(Bio-Rad, Hercules, CA). ADAM17 activity was measured in 200 ug of total hemocyte lysate, or 10 ug of cell 
culture lysate, via the InnoZyme fluorometric TACE activity kit (EMD Millipore, Temecula, CA) per manufacture 
instructions. Fluorometric readings were obtained using the Synergy HT multi-mode microplate reader (BioTek). 
Due to the reversible nature of ADAM17 inhibition by Marimastat, experimental concentrations of drug were 
maintained in assay buffers when testing samples from inhibitor-treated conditions.
Phase contrast microscopy and image-based morphological quantification. Phase con-
trast images of primary leukocyte cultures were obtained from an AxioObserver inverted microscope (Ziess, 
Thornwood, NY) equipped with a AxioCam mR5 digital camera (Ziess) using the AxioVision imaging software 
suite (Ziess). Scale bars were generated via imaging of a 0.07–1.50 mm scale calibration slide (Motic, Richmond, 
BC, CA).
A basic point-counting system was used for image-based morphological quantification of monocyte cultures. 
Three randomly selected images from each culture were overlaid with a 9 × 12 grid. Each intersecting point of the 
grid (108 points per image) was assessed for the presence of a cell; if a cell was present, it was determined whether 
it was adherent, as well as whether it contained clearly defined internal vacuolar structures. The percentage of 
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adherent cells, as well as the percentage of cells containing vacuoles, was than calculated, both relative to the total 
number of cells analyzed. Images were analyzed in random order and counters were blinded to experimental 
information.
Statistical analysis and data availability. Statistics were performed using SPSS (IBM, Chicago, Ill) in 
combination with R 2.14 (R project for statistical computing)74 via the SPSS R integration plug-in. Fisher’s exact 
test was used for comparison of dichotomous variables. Student t-test, one-way ANOVA, one-way ANCOVA, 
or repeated measures one-way ANOVA was used for comparison of continuous variables where appropriate. In 
some instances of ANCOVA and one-way ANOVA, data were log-transformed prior to analysis in order to meet 
normality and homogeneity of variance assumptions, which were evaluated via the Shapiro-Wilk test and Levene’s 
test. In some instances of repeated measures one-way ANOVA, values were adjusted via the Greenhouse-Geisser 
correction to account for non-sphericity, which was assessed using Mauchly’s test. Either Spearman’s rho or 
Pearson’s r was used to assess the strength of correlational relationships where appropriate based on level of 
homoscedasticity. Principle components analysis was used for dimensionality reduction; prior to analysis, data 
were tested for sphericity and sampling adequacy via Bartlett’s test and the Kaiser-Mayer-Olkin index. The level 
of significance was established at 0.05 for all statistical testing. In the cases of multiple comparisons, p-values were 
adjusted using Bonferroni correction. Parameters of all statistical tests performed are outlined in detail within 
the figure legends. The datasets generated and analyzed during this study are available from the corresponding 
author upon reasonable request.
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